{"id":1013860,"date":"2026-10-27T06:48:07","date_gmt":"2026-10-27T10:48:07","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/pfizers-elrexfio-outperforms-standard-regimens-and-meets-primary-endpoint-in-phase-3-study-in-relapsed-or-refractory-multiple-myeloma\/"},"modified":"2026-10-27T06:48:07","modified_gmt":"2026-10-27T10:48:07","slug":"pfizers-elrexfio-outperforms-standard-regimens-and-meets-primary-endpoint-in-phase-3-study-in-relapsed-or-refractory-multiple-myeloma","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/pfizers-elrexfio-outperforms-standard-regimens-and-meets-primary-endpoint-in-phase-3-study-in-relapsed-or-refractory-multiple-myeloma\/","title":{"rendered":"Pfizer\u2019s ELREXFIO Outperforms Standard Regimens and Meets Primary Endpoint in Phase 3 Study in Relapsed or Refractory Multiple Myeloma"},"content":{"rendered":"

<\/p>\n

Pfizer\u2019s ELREXFIO Outperforms Standard Regimens and Meets Primary Endpoint in Phase 3 Study in Relapsed or Refractory Multiple Myeloma<\/b><\/p>\n

In the Phase 3 MagnetisMM-32 trial, ELREXFIO demonstrated a clinically meaningful and statistically significant benefit for patients whose disease progressed after anti-CD38 therapy and lenalidomide, with median PFS not yet reached<\/i><\/p>\n

NEW YORK–(BUSINESS WIRE<\/a>)–Pfizer Inc.<\/a> (NYSE: PFE) today announced topline results from the Phase 3 MagnetisMM-32 study evaluating ELREXFIO\u00ae<\/sup> (elranatamab) as monotherapy in adults with relapsed or refractory multiple myeloma (RRMM) who received at least one prior line of treatment with anti-CD38 therapy (daratumumab or isatuximab) and lenalidomide.<\/p>\n

\nAt the pre-specified interim analysis for efficacy, the study met its primary endpoint of progression-free survival (PFS) as assessed by blinded independent central review (BICR). ELREXFIO demonstrated a statistically significant and clinically meaningful reduction in the risk of disease progression or death versus investigator\u2019s choice of elotuzumab, pomalidomide and dexamethasone (EloPd); pomalidomide, bortezomib and dexamethasone (PVd); or carfilzomib and dexamethasone (Kd). MagnetisMM-32 used one of the broadest standard-of-care comparators in a Phase 3 BCMA bispecific trial in this setting, with investigator\u2019s choice of three established regimens.<\/p>\n

\nMore than 75% of patients receiving ELREXFIO had not experienced disease progression or death from any cause at the time of the analysis1<\/sup>, with an estimated 68% PFS at 18 months. Data for overall survival (OS), a key secondary endpoint, remain immature, and follow-up will continue to the next pre-specified OS analysis.<\/p>\n

\nThe safety profile of ELREXFIO in MagnetisMM-32 was consistent with its known profile and no new safety signals were identified. Infection prophylaxis measures instituted from the beginning of the study helped mitigate infection risk, including Grade 3 or higher infections. Grade \u22653 infections were observed in 27.5% of patients receiving ELREXFIO vs. 18.1% of patients on investigator\u2019s choice, and Grade 5 infections were observed in 0.8% of patients receiving ELREXFIO vs 1.6% of patients on investigator\u2019s choice.<\/p>\n

\nPfizer plans to submit these data to global health authorities, with detailed results to be shared at a future medical meeting and submitted for publication.<\/p>\n

\n\u201cThe treatment landscape for multiple myeloma continues to evolve as anti-CD38-based regimens and lenalidomide are increasingly used earlier in care. Yet many patients ultimately experience disease progression, with limited treatment options available following these commonly used therapies. MagnetisMM-32 demonstrates that ELREXFIO, an off-the-shelf, fixed-dose monotherapy, delivers a significant and clinically meaningful progression-free survival benefit and an encouraging safety profile in this increasingly important treatment setting, with median PFS not yet reached and a high percentage of patients remaining progression-free at the time of analysis. These findings further strengthen the rationale for moving BCMA-directed therapy earlier in the treatment journey and underscore ELREXFIO’s potential to help redefine outcomes for patients.\u201d<\/p>\n

\u2013 Jeff Legos, Chief Oncology Officer, Pfizer<\/b><\/p>\n

\n\u201cThe MagnetisMM-32 results are particularly compelling given the rigorous and clinically relevant benchmark of three established standard-of-care regimens. Demonstrating a significant progression-free survival benefit against this active control highlights the potential of elranatamab-bcmm to provide an important treatment option for patients whose disease has progressed following anti-CD38 therapy and lenalidomide.\u201d<\/p>\n

\u2013 C. Ola Landgren, Professor of Medicine, Chief of Myeloma Division and Director of Sylvester Myeloma Institute, University of Miami Miller School of Medicine<\/b><\/p>\n

About the Phase 3 MagnetisMM-32 Study
\n
<\/b>These data build on the positive topline results previously announced<\/a> from MagnetisMM-5, the first Phase 3 study of ELREXFIO to read out in double-class exposed RRMM, and reinforce the evidence supporting ELREXFIO monotherapy in earlier lines of RRMM. The MagnetisMM-32 findings show that ELREXFIO has the potential to address a significant unmet need for patients whose disease has progressed following anti-CD38 therapy and lenalidomide, a growing population that often faces poorer outcomes and has limited treatment options.2,3<\/sup><\/p>\n